Sava Infond
ALNY icon

Sava Infond’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sava Infond’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$218K Hold
885
– – 0.01% 183
2026
Q2 		$266K Sell
885
-400
-31% -$121K 0.02% 173
2026
Q1 		$425K Hold
1,285
– – 0.06% 147
2025
Q4 		$511K Sell
1,285
-355
-22% -$157K 0.07% 129
2025
Q3 		$748K Sell
1,640
-540
-25% -$220K 0.11% 110
2025
Q2 		$711K Buy
2,180
+100
+5% +$27.7K 0.11% 110
2025
Q1 		$562K Buy
2,080
+350
+20% +$89.9K 0.11% 117
2024
Q4 		$407K Buy
+1,730
New +$455K 0.07% 126

Other funds holding ALNY

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Sava Infond's ALNY Position: Q3 2026 in Review

Sava Infond held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2026 at 885 shares worth $218K. The position accounts for 0.01% of the portfolio, ranked #183.

Sava Infond first reported a position in ALNY in Q4 2024 and has held it in 8 quarters since. The position peaked at $748K in Q3 2025. 328 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Sava Infond held 885 shares of Alnylam Pharmaceuticals worth $218K as of Q3 2026.
  • Sava Infond left its Alnylam Pharmaceuticals share count unchanged in Q3 2026.
  • Alnylam Pharmaceuticals made up 0.01% of Sava Infond's portfolio in Q3 2026, its #183 holding.
  • Sava Infond first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • Sava Infond's Alnylam Pharmaceuticals position peaked at $748K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Sava Infond's 13F filing for Q3 2026, filed 28 Oct 2026.